MediWound (NASDAQ:MDWD – Get Free Report) and Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations.
Institutional & Insider Ownership
46.8% of MediWound shares are owned by institutional investors. Comparatively, 97.3% of Pliant Therapeutics shares are owned by institutional investors. 9.2% of MediWound shares are owned by insiders. Comparatively, 8.7% of Pliant Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of current ratings and recommmendations for MediWound and Pliant Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MediWound | 1 | 0 | 4 | 0 | 2.60 |
| Pliant Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
MediWound presently has a consensus price target of $33.00, suggesting a potential upside of 137.48%. Pliant Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 291.13%. Given Pliant Therapeutics’ higher probable upside, analysts plainly believe Pliant Therapeutics is more favorable than MediWound.
Valuation & Earnings
This table compares MediWound and Pliant Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MediWound | $16.96 million | 10.66 | -$23.88 million | ($1.80) | -7.72 |
| Pliant Therapeutics | $1.58 million | 30.06 | -$149.34 million | ($1.49) | -0.51 |
MediWound has higher revenue and earnings than Pliant Therapeutics. MediWound is trading at a lower price-to-earnings ratio than Pliant Therapeutics, indicating that it is currently the more affordable of the two stocks.
Risk and Volatility
MediWound has a beta of 0.07, suggesting that its share price is 93% less volatile than the S&P 500. Comparatively, Pliant Therapeutics has a beta of 1.36, suggesting that its share price is 36% more volatile than the S&P 500.
Profitability
This table compares MediWound and Pliant Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MediWound | -170.10% | -47.24% | -24.27% |
| Pliant Therapeutics | N/A | -52.17% | -40.46% |
About MediWound
MediWound Ltd. (NASDAQ: MDWD) is a commercial-stage biotechnology company focused on developing and marketing innovative enzymatic therapies for complex wounds. The company’s products are designed to support the removal of damaged tissue and improve wound management, with an emphasis on severe burns and hard-to-heal chronic wounds. MediWound’s lead product, NexoBrid, is a bromelain-based topical biological product used for the enzymatic removal of eschar, or dead tissue, from deep partial-thickness and full-thickness thermal burns.
About Pliant Therapeutics
Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. The company’s research is centered on integrin biology, a field involving proteins that regulate cell communication and tissue remodeling. Pliant aims to develop medicines that address the underlying processes that drive fibrosis in organs such as the lungs and liver. Pliant’s lead investigational product is bexotegrast, an oral, selective inhibitor of the integrins αvβ1 and αvβ6.
Receive News & Ratings for MediWound Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediWound and related companies with MarketBeat.com's FREE daily email newsletter.
